Mood and Anxiety Disorders ProgramEmory University School of Medicine
Psychiatry
Dr. Boadie W. Dunlop, MD
|
|
Give Review
Boadie Dunlop works in the field of Psychiatry. He researched medicine at Mayo Medical School. Mayo Medical School is ranked 27 in research and 42 in primary care medicine Boadie Dunlop is also published. He has 54 publications published. The lastest publication: "Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Prediction of treatment outcomes in major depressive disorder.
- Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis.
- Pretreatment brain states identify likely nonresponse to standard treatments for depression.
- How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
- Mediators of Sexual Functioning and Marital Quality in Chronically Depressed Adults with and Without a History of Childhood Sexual Abuse.
- Ziprasidone monotherapy is ineffective for bipolar-associated anxiety.
- Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and s...
- Cognitive Effects of Quetiapine XR in Patients With Euthymic Bipolar Disorder.
- REVIEW OF NUTRITIONAL SUPPLEMENTS FOR THE TREATMENT OF BIPOLAR DEPRESSION.
- Reconciling Variable Findings of White Matter Integrity in Major Depressive Disorder.
- Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder.
- Toward a neuroimaging treatment selection biomarker for major depressive disorder.
- ENHANCING HISPANIC PARTICIPATION IN MENTAL HEALTH CLINICAL RESEARCH: DEVELOPMENT OF A SPANISH-SPEAKING DEPRESSION RESEARCH SITE.
- The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.
- Do alcohol use disorders destabilize the course of bipolar disorder?
- Recovery and subsequent recurrence in patients with recurrent major depressive disorder.
- US psychiatric residents' treatment of patients with bipolar disorder.
- Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.
- Public health consequences of state immigration laws.
- Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
- The effects of sertraline on psychopathic traits.
- Preconsent education about research processes improved African Americans' willingness to participate in clinical research.
- Conceptualizing Treatment Nonadherence in Patients with Bipolar Disorder and PTSD.
- Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review.
- An additional consideration for comparisons of antidepressants versus placebo.
- Should sensitive information from clinical trials be included in electronic medical records?
- Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials.
- Exploratory structural equation modeling of resting-state fMRI: applicability of group models to individual subjects.
- Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study.
- Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review.
- Exercise for depression: efficacy, safety and clinical trial implications.
- The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
- Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a...
- Use of dialectical behavior therapy in borderline personality disorder: a view from residency.
- The role of dopamine in the pathophysiology of depression.
- Psychosocial context of antidepressant response.
- Neurobiology and etiology of panic disorder.
- Counseling via analogy: improving patient adherence in major depressive disorder.
- Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.
- Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP).
- Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results.
- Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996.
- A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders.
- BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity.
- The impact of HIPAA authorization on willingness to participate in clinical research.
- Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.
- Tiagabine for social anxiety disorder.
- Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary ana...
- Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
- Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.
- Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder.
- Will current socioeconomic trends produce a depressing future for men?
- Correlation between patient and clinician assessments of depression severity in the PREVENT study.
Schools
Mayo Medical School
Emory University
Doctors Specialties
- Psychiatry
Accepted Insurances
- Aetna
- Blue Card PPO
- Blue Choice HMO
- Blue Choice Option POS
- Blue Open Access POS
- Cigna
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Preferred PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- United Healthcare
Education
-
Emory University -
Mayo Medical School
Hospital
-
Emory University Hospital
Drug Facts
| NPI NUMBER | 1558467605 | |
| NPPES Provider LastName | DUNLOP | |
| NPPES Provider FirstName | BOADIE | |
| NPPES Provider ZIPCode | 303220001 | |
| NPPES Provider State | GA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 65.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558467605 |
| Last Name Of The Provider | DUNLOP |
| First Name Of The Provider | BOADIE |
| View All |
Similar Doctors
|
|
Dr. Pedro F. Garcia, MD |
|
|
Dr. Jennifer F. Fortner, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Viorica M. Pencea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheril O. Kalarithara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jesse P. McClelland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria T. Koshy, MD |
|
|
Dr. Valrie M. Honablue, MD |